Royalty Report: Drugs, Cancer, Therapeutic – Collection: 241600

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Disease
  • Specialty
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 241600

License Grant
The Licensor grants to the Cayman Islands Licensee an exclusive royalty-bearing, non-sublicensable, non-transferable license under the Licensor Technology and interest in the Joint Combination Therapy Technology to Commercialize Licensed Products in the Field in the Territory.
License Property
Technology relates to he oral inhibitor enzyme is Ivosidenib for the treatment of hematologic and solid tumor indications.  Ivosidenib is an investigational, first-in-class, oral, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme.

Ivosidenib is an investigational first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein and is a highly targeted investigational medicine for the treatment of patients with cancers that harbor an IDH1 mutation. IDH1 is a metabolic enzyme that is mutated in a wide range of cancers, including acute myeloid leukemia, cholangiocarcinoma and glioma. Ivosidenib is currently under U.S. FDA priority review for IDH1m R/R AML patients with a PDUFA action date of August 21, 2018.

Field of Use
Licensee has expertise in the development of biopharmaceutical products and will be responsible for conducting the development and commercialization activities for ivosidenib in hematologic and solid tumor indications.

IPSCIO Record ID: 328906

License Grant
By this Purchase and Sale agreement, Seller is selling its commercial, clinical and research-stage oncology portfolio to the Buyer.

At the Closing, Seller shall sell, assign, transfer and convey all of Seller’s and the other Seller Entities’ right, title and interest as of the Closing in and to the Purchased Assets, which include any and all Intellectual Property primarily used, or held primarily for use, in the operation of the Business or set forth in the Business Intellectual Property.

Effective as of the Closing, Seller grants to Purchaser a worldwide, non-exclusive, perpetual, irrevocable, with Seller’s prior written consent, sub-licensable license to all Intellectual Property that is
(a) owned by Seller and its Subsidiaries as of the Closing Date,
(b) required for the research, development, manufacturing, use or commercialization of the Products, and
(c) not included in the Business Intellectual Property solely for the purpose of Exploiting the Products in the Business Field.

Seller hereby grants to Purchaser and its Affiliates a limited, worldwide, non-exclusive, non-transferable, sublicensable, royalty-free right to continue to use the Sellers Name and Marks on packaging, labeling, and educational, payer and marketing materials, including online materials, associated with TIBSOVO® until the later of (i) the date that is eighteen (18) month anniversary of Closing and (ii) the date that is twelve (12) months after Purchaser’s receipt of all necessary approvals from the FDA for replacement packaging associated with TIBSOVO®, and, as permitted by the Transition Services Agreement for the term of the applicable service. Purchaser and its Affiliates shall have the right to grant sublicenses solely (A) with the prior written consent of Seller (such consent not to be unreasonably withheld, conditioned or delayed) or (B) consistent with licenses or sublicenses granted prior to Closing under the Specified Business Contracts.

From the Closing Date until the Loss of Exclusivity with respect to each Earn-Out Product, Purchaser and its Affiliates may not, directly or indirectly, by a sale or swap of assets, merger, reorganization, joint venture, lease, license or any other similar transaction or arrangement, sell, transfer, convey or otherwise dispose of their respective rights in and to such Earn-Out Product to a third party.

License Property
Seller is in the field of cellular metabolism to treat cancer and rare genetic diseases.

TIBSOVO means any product containing or comprising ivosidenib, NDC 71334-100.

Vorasidenib means an isocitrate dehydrogenase-1 & 2 (IDH1 & 2) inhibitor that has the compound AG-881 as its active ingredient.

Vorasidenib Companion Diagnostic Test means the companion diagnostic test used in connection with Vorasidenib that identifies IDH1 and IDH2 mutations in glioma patient samples.

Combination Product means an Earn-Out Product that is comprised of or contains TIBSOVO or Vorasidenib together with one or more other active ingredients (other than TIBSOVO or Vorasidenib), whether in the same or different formulations, and is sold either as a fixed dose or as separate doses as one product.

Business means the worldwide oncology business, operations, activities and programs of Seller and its Subsidiaries as of immediately prior to the Closing with respect to the discovery, research, development, manufacture, registration, commercialization, importation, distribution, sale and marketing of chemical or biological entities, pharmaceutical products, medicines, therapies, compounds, programs, or in vitro diagnostic or other devices, in each case, for patients in the areas of hematologic malignancies, solid tumors and other malignant diseases (collectively, the Business Field), including (a) all activities of Seller and its Subsidiaries as of immediately prior to the Closing related to ivosidenib (TIBSOVO®), enasidenib (IDHIFA®), vorasidenib, AG-270 and AG-636 and the products listed the Seller Disclosure Schedules (including as conducted through joint ventures, collaborations or similar arrangements) as of immediately prior to the Closing, and (b) any and all applications of such chemical or biological entities, pharmaceutical products, medicines, therapies, compounds, programs or in vitro diagnostic or other devices in any field, including any Retained Businesses Field.

Field of Use
The TIBSOVO® field of use is as monotherapy for the treatment of adults with IDH1-mutant relapsed or refractory acute myeloid leukemia (AML) and for adults with newly diagnosed IDH1-mutant AML who are ³75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

The vorasidenib field of use is as an investigational, brain-penetrant, dual inhibitor of mutant IDH1 and IDH2 which is currently being studied in the registration-enabling Phase 3 INDIGO study in patients with IDH-mutant low-grade glioma; AG-270, an investigational first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor being evaluated in combination with taxanes in patients with methylthioadenosine phosphorylase (MTAP)-deleted non-small cell lung cancer and pancreatic cancer; AG-636, a novel inhibitor of dihydroorotate dehydrogenase (DHODH); and Seller’s oncology research programs.

Collectively, the Business Field is chemical or biological entities, pharmaceutical products, medicines, therapies, compounds, programs, or in vitro diagnostic or other devices, in each case, for patients in the areas of hematologic malignancies, solid tumors and other malignant diseases.

IPSCIO Record ID: 239202

License Grant
The Licensor entered into an exclusive license agreement with Licensee  for the development and commercialization of certain products containing ivosidenib in the forms clinically developed by the Company (Licensed Products) in mainland China, Hong Kong, Macau and Taiwan (the Territory), either as a monotherapy or in combination with other therapies, in all therapeutic uses in humans, excluding brain cancer, unless later added by the Company in its sole discretion (the Field). The Company retains development and commercialization rights with respect to Licensed Products in the rest of the world.

Pursuant to the License Agreement, Licensee will initially be responsible for the development and commercialization of Licensed Products in acute myeloid leukemia (AML) and cholangiocarcinoma in the Territory, as well as other indications that the parties mutually agree to in the future. Licensee will also be responsible, at the Company’s discretion, for the development and commercialization of Licensed Products in brain cancer indications in the Territory. The Company has granted Licensee specified intellectual property licenses to enable Licensee to perform its obligations and exercise its rights under the License Agreement, including license grants to enable Licensee to conduct development and commercialization activities pursuant to the terms of the License Agreement.

License Property
The products are certain products containing ivosidenib in the forms clinically developed by the Company.

Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer.

Field of Use
The Field is in all therapeutic uses in humans, excluding brain cancer, unless later added by the Company in its sole discretion.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.